Internal Medicine, Pulmonary Disease · New Haven, CT
NPI
1811970577
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
789 Howard Ave, Fitkin Building
New Haven, CT, 06519
Phone (203) 785-4198
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
377 services
Medicare patients, 2024
145
Average age 74
Drug cost, 2024
$1.6M
1,387 prescriptions
Company payments, 2025
$75K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Geoffrey L Chupp was code 99214 (office e&m - established), 102 times for 73 patients. In total Geoffrey L Chupp billed 377 services in 21 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-06-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 102 | 73 | $76.80 | $7,833 |
| 94375 Pulmonary Function Testing | Office | 48 | 40 | $11.47 | $550 |
| 99291 Critical Care E&M | Facility | 37 | 16 | $167.84 | $6,210 |
| 94729 Pulmonary Function Testing | Office | 35 | 31 | $6.89 | $241 |
| 94727 Pulmonary Function Testing | Office | 30 | 27 | $9.23 | $277 |
| 99214 Office E&M - Established | Facility | 28 | 24 | $75.00 | $2,100 |
| 99233 Hospital E&M - Subsequent | Facility | 16 | 12 | $95.57 | $1,529 |
By year: 2022 $18K for 215 services; 2023 $22K for 273 services; 2024 $22K for 377 services.
Medicare prescription drug claims, 2024
In 2024, the drug Geoffrey L Chupp prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 166 prescriptions and refills. In total Geoffrey L Chupp wrote 1,387 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 166 | 222 | 33 | $143K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 156 | 186 | 64 | $4,136 |
| Montelukast Sodium Generic | 106 | 269 | 29 | $1,167 |
| Breo Ellipta Fluticasone/Vilanterol | 78 | 116 | 16 | $44K |
| Symbicort Budesonide/Formoterol Fumarate | 78 | 111 | 21 | $24K |
| Dupixent Pen Dupilumab | 74 | 79 | Under 11 | $290K |
| Nucala Mepolizumab | 63 | 63 | Under 11 | $480K |
| Prednisone Generic | 60 | 73 | 30 | $511 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 54 | 80 | 14 | $11K |
| Azithromycin Generic | 43 | 62 | 27 | $277 |
| Arnuity Ellipta Fluticasone Furoate | 36 | 58 | Under 11 | $14K |
| Ventolin Hfa Albuterol Sulfate | 35 | 39 | 11 | $2,350 |
| Tezspire Tezepelumab-Ekko | 31 | 31 | Under 11 | $136K |
| Spiriva Respimat Tiotropium Bromide | 27 | 34 | Under 11 | $18K |
| Dupixent Syringe Dupilumab | 24 | 24 | Under 11 | $87K |
Brand drugs: 942 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Geoffrey L Chupp $75K ($73K in general payments such as food, travel and fees and $2,200 for research) from 8 companies. The largest payer was GlaxoSmithKline, LLC. with $30K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.